alexa Remarkable Efficacy On RA Therapy With Interleukin 6 (IL-6) Blocking Agent, Tocilizumab
ISSN: 2329-9096

International Journal of Physical Medicine & Rehabilitation
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference and Exhibition on Physical Medicine & Rehabilitation
July 14-16, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Kazuyuki Yoshizaki
ScientificTracks Abstracts: Int J Phys Med Rehabil
DOI: 10.4172/2329-9096.S1.006
Abstract
I t has been known that the anti-IL-6 receptor antibody, tocilizumab, is one of the most effective biologics for the treatment of patients with rheumatoid arthritis (RA). Recently, the head to head clinical study without methotrexate between tocilizumab and adalimumab clearly showed the superiority of tocilizumab on the signs and symptoms of RA (ADACTA trial). It was reported that tocilizumab induced the decrease of CRP and SAA levels in serum better than TNF-α blockade, and improved chronic inflammatory anemia via inhibition of hepcidin better than TNF-α blockade. Moreover, tocilizumab therapy showed remarkable clinical efficacy without combination of methotrexate. Not only clinical efficacy, but also most of laboratory findings were getting better and normalized, such as CRP, SAA, Fib, Hb, CH50, and MMP-3. These data suggested that tocilizumab, an IL-6 blockade inhibits the inflammatory status better than TNF-α blockade. Now, we are trying to use tocilizumab for the treatment of most of chronic inflammatory disease rather than RA, Castleman?s disease, juvenile inflammatory arthritis, such as inflammatory autoimmune disease, auto-inflammatory disease, Crohn?s disease, multiple sclerosis, Still?s disease, vasculitis syndrome, and cachexia caused by malignancy.
Biography
Kazuyuki Yoshizaki found BCDF (1981), former Interleukin 6 (IL-6) in 1986. He analyzed IL-6 in the pathogenesis of immunological disorders, such as Castleman?s disease (CD) in 1989 and rheumatoid arthritis (RA) in 1990. After humanized anti-IL-6 receptor antibody (named tocilizumab) in 1992, he engaged in the establishment of IL-6 blocking therapy with tocilizumab for CD, RA and juvenile idiopathic arthritis (sJIA) from 1993.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords